ライフサイエンスコーパス: non-Hodgkin lymphoma

1 ) is the third most common subtype of B-cell non-Hodgkin lymphoma.

2 mphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma.

3 ombination is not being developed further in non-Hodgkin lymphoma.

4 classification, applies to both Hodgkin and non-Hodgkin lymphoma.

5 hazard rate decreased for Kaposi sarcoma and non-Hodgkin lymphoma.

6 refractory acute lymphoblastic leukaemia or non-Hodgkin lymphoma.

7 vasculitis to glomerulonephritis and B-cell non-Hodgkin lymphoma.

8 ab in patients with relapsed indolent B-cell non-Hodgkin lymphoma.

9 studies of patients with relapsed/refractory non-Hodgkin lymphoma.

10 ell lymphoma (ALCL) is an aggressive CD30(+) non-Hodgkin lymphoma.

11 eloid leukaemia, and 0.940 (0.897-0.984) for non-Hodgkin lymphoma.

12 l nervous system lymphoma, and 7 (13%) other non-Hodgkin lymphoma.

13 fective as monotherapy for relapsed indolent non-Hodgkin lymphoma.

14 th previously untreated CD20-positive B-cell non-Hodgkin lymphoma.

15 ents with untreated, advanced stage indolent non-Hodgkin lymphoma.

16 hly active as initial treatment for indolent non-Hodgkin lymphoma.

17 athologically confirmed CD20-positive B-cell non-Hodgkin lymphoma.

18 r, kidney, prostate, and ovarian cancers and non-Hodgkin lymphoma.

19 fety profile in relapsed/refractory indolent non-Hodgkin lymphoma.

20 veillance after curative-intent treatment of non-Hodgkin lymphoma.

21 and that TCE may also cause liver cancer and non-Hodgkin lymphoma.

22 n patients with relapsed/refractory indolent non-Hodgkin lymphoma.

23 ta exist for the treatment of HIV-associated non-Hodgkin lymphoma.

24 and tumor, and 68.5% +/- 6.4% for those with non-Hodgkin lymphoma.

25 toxicity for pediatric patients with B-cell non-Hodgkin lymphoma.

26 otherapy represents the standard-of-care for non-Hodgkin lymphoma.

27 as, and the remaining 90% are referred to as non-Hodgkin lymphoma.

28 ients with relapsed or refractory aggressive non-Hodgkin lymphoma.

29 er, smoking-related cancers, and Hodgkin and non-Hodgkin lymphoma.

30 due to testicular cancer; and 829396 due to non-Hodgkin lymphoma.

31 atients with relapsed CD37-positive indolent non-Hodgkin lymphoma.

32 ome central to the evaluation of Hodgkin and non-Hodgkin lymphoma.

33 al for patients with relapsed CD37+ indolent non-Hodgkin lymphoma.

34 oma (FL) is the most common form of indolent non-Hodgkin lymphoma.

35 an uncommon yet devastating complication of non-Hodgkin lymphomas.

36 ug conjugate, in relapsed/refractory CD30(+) non-Hodgkin lymphomas.

37 heterogeneous and poorly understood group of non-Hodgkin lymphomas.

38 ents with relapsed and refractory aggressive non-Hodgkin lymphomas.

39 phoma (DLBCL) accounting for 2% to 4% of all non-Hodgkin lymphomas.

40 nferior responses in MCL compared with other non-Hodgkin lymphomas.

41 n aggressive and incurable subtype of B-cell non-Hodgkin lymphomas.

42 monoclonal B-cell lymphocytosis, and CD5(-) non-Hodgkin lymphomas.

43 l center (GC) and is expressed in GC-derived non-Hodgkin lymphomas.

44 (GOF) EZH2 mutations have been identified in non-Hodgkin lymphomas.

45 e Myeloma, 3 Chronic Lymphocytic Leukemia, 1 Non-Hodgkin Lymphoma, 1 Chronic Myeloid Leukemia, 2 Seve

46 s (Kaposi's sarcoma [498.11, 477.82-519.03], non-Hodgkin lymphoma [11.51, 11.14-11.89], and cervix [3

47 sions, including 9 of 22 (41%) decisions for non-Hodgkin lymphoma, 16 of 76 (21%) for breast cancer,

48 5-year survival was 42% lower for secondary non-Hodgkin lymphoma, 19% for secondary breast carcinoma

49 % for AIDS-defining cancers (ADCs, including non-Hodgkin lymphoma, 2.0% of deaths) and 7.1% for non-A

50 oma) compared with primary CL (37% low-grade non-Hodgkin lymphoma, 27% extranodal marginal zone lymph

51 e additional patient was diagnosed as having non-Hodgkin lymphoma 3 months after the onset of CMV-ass

52 as follows: Kaposi sarcoma, 4.4% and 0.01%; non-Hodgkin lymphoma, 4.5% and 0.7%; lung cancer, 3.4% a

53 splenomegaly was performed most commonly for non-Hodgkin lymphoma (48%) and myeloid metaplasia (31%).

54 4% [95% CI 72.9-73.9] vs 81.7% [81.3-82.1]), non-Hodgkin lymphoma (53.8% [53.3-54.4] vs 60.4% [60.0-6

55 were breast cancer (92 patients, 426 scans), non-Hodgkin lymphoma (77 patients, 208 scans), Hodgkin d

56 were breast cancer (92 patients, 426 scans), non-Hodgkin lymphoma (77 patients, 208 scans), Hodgkin d

57 llicular lymphoma (FL) is an indolent B-cell non-Hodgkin lymphoma able to transform into germinal cen

58 lder patients for thyroid, Hodgkin lymphoma, non-Hodgkin lymphoma, acute myeloid leukemia, soft-tissu

59 8 children (6.6%) with non Hodgkin lymphoma and 11 (9%) with Hodgkin lymphoma w

60 n anti-CD20 monoclonal antibody approved for non Hodgkin lymphoma and rheumatoid arthritis.

61 An EL4 mouse model of non-Hodgkin lymphoma and a B16 mouse model of subcutaneo

62 non-Hodgkin lymphomas or a combination of a non-Hodgkin lymphoma and a Hodgkin's lymphoma.

63 Twenty-six patients with advanced non-Hodgkin lymphoma and acute lymphoblastic leukemia sa

64 e B-cell lymphoma (DLBCL) is the most common non-Hodgkin lymphoma and an aggressive malignancy.

65 of the translocation in multiple subtypes of non-Hodgkin lymphoma and distinguished a unique molecula

66 t data regarding transplantation in indolent non-Hodgkin lymphoma and highlights the issues relevant

67 r burden in the region, and the incidence of non-Hodgkin lymphoma and Hodgkin lymphoma is rapidly inc

68 ver time in QOL among long-term survivors of non-Hodgkin lymphoma and identified demographic, clinica

69 f this approach as a screening technique for non-Hodgkin lymphoma and melanoma skin cancer.

70 ata raising concerns about associations with non-Hodgkin lymphoma and multiple myeloma.

71 iling data set including 249 cases of T-cell non-Hodgkin lymphoma and normal T cells.

72 e the roles of autoHCT and alloHCT in T-cell non-Hodgkin lymphoma and suggest greater effectiveness e

73 gous transplantation for Hodgkin lymphoma or non-Hodgkin lymphoma and targeted sequencing on cryopres

74 in understanding the biology and genetics of non-Hodgkin lymphoma and the availability of new diagnos

75 However, in many composite non-Hodgkin lymphomas and Hodgkin's lymphomas, the tumou

76 dder, as well as leukemia, multiple myeloma, non-Hodgkin lymphoma, and breast cancer in postmenopausa

77 6-2012 for Kaposi's sarcoma, two subtypes of non-Hodgkin lymphoma, and cancer of the anus, liver, and

78 ays durable responses in relapsed/refractory non-Hodgkin lymphoma, and combination with rituximab and

79 o high-grade non-Hodgkin lymphoma, low-grade non-Hodgkin lymphoma, and Hodgkin lymphoma was 90%, 100%

80 rituximab is the standard of care in B-cell non-Hodgkin lymphoma, and is administered over 1.5-6 h.

81 cidences by age 75 years for Kaposi sarcoma, non-Hodgkin lymphoma, and lung cancer support early and

82 s apoptosis in acute myeloid leukemia (AML), non-Hodgkin lymphoma, and multiple myeloma cells.

83 loid leukemia, chronic lymphocytic leukemia, non-Hodgkin lymphoma, and multiple myeloma) and 9 treatm

84 ctions of Gilbert syndrome, Graves' disease, non-Hodgkin lymphoma, and various blood groups were accu

85 (MDS), myeloproliferative neoplasms (MPNs), non-Hodgkin lymphomas, and classical Hodgkin lymphoma.

86 renal cell cancers and most breast cancers, non-Hodgkin lymphomas, and medullary thyroid cancers rep

87 to the treatment of advanced stages of this non-Hodgkin lymphoma are clearly warranted.

88 Combined B-cell non-Hodgkin lymphomas are often clonally unrelated.

89 Standard treatments for indolent non-Hodgkin lymphomas are often toxic, and most patients

90 ectal cancer, leukaemia, thyroid cancer, and non-Hodgkin lymphomas are the most common cancers affect

91 toxicity, warranting further study in B-cell non-Hodgkin lymphoma as a platform for addition of novel

92 Bone marrow showed clear non-Hodgkin lymphoma as the underlying disorder in 54% o

93 ute myeloid leukaemias, Hodgkin's lymphomas, non-Hodgkin lymphomas, astrocytomas, Ewing's sarcomas, a

94 olled study in adults with multiple myeloma, non-Hodgkin lymphoma (B- or T-cell), Hodgkin lymphoma, o

95 Its role in the development of B cell non-Hodgkin lymphoma (B-NHL) is becoming better understo

96 apsed/refractory B-cell malignancies such as non-Hodgkin lymphoma (B-NHL) or acute lymphoblastic leuk

97 ed phosphorylation may be involved in B-cell non-Hodgkin lymphoma (B-NHL) pathogenesis is largely unk

98 lymphoma (BL) is a highly aggressive B-cell non-Hodgkin lymphoma (B-NHL), which originates from germ

99 in the pathogenesis of many types of B-cell non-Hodgkin lymphoma (B-NHL).

100 ll transformation and is a driver for B-cell non-Hodgkin lymphoma (B-NHL).

101 Among human B-cell non-Hodgkin lymphomas (B-NHL), primary effusion lymphoma

102 We have shown that human B-cell non-Hodgkin lymphomas (B-NHLs) express heat shock protei

103 lymphoma, mucosa-associated lymphoid tissue non-Hodgkin lymphoma, B-cell chronic lymphocytic leukemi

104 cts from 401 patients who underwent ASCT for non-Hodgkin lymphoma between 2003 and 2010.

105 IL-10R2 (n = 4) deficiency developed B-cell non-Hodgkin lymphoma between the ages of 5 and 6 years (

106 be used as stratification criteria in coming Non-Hodgkin Lymphoma-BFM trials.

107 (prostate, colorectal, non-small-cell lung, non-Hodgkin lymphoma, breast, uterine, or cervical) from

108 CD27 is expressed on a majority of B-cell non-Hodgkin lymphoma, but its role in the immune control

109 cancer, prostate cancer, skin melanoma, and non-Hodgkin lymphoma, but low for kidney, stomach, ovari

110 ld improve responses in patients with B-cell non-Hodgkin lymphoma, but our findings need confirmation

111 is overexpressed in three different types of non-Hodgkin lymphoma cell lines and clinical samples as

112 more, we demonstrate that PRMT5 knockdown in non-Hodgkin lymphoma cell lines and mouse primary lympho

113 sion of mantle cell lymphoma (MCL) and other non-Hodgkin lymphoma cells to lymphoma stromal cells con

114 cell lymphoma (MCL) is a distinct subtype of non-Hodgkin lymphoma characterized by overexpression of

115 n lymphoma (PEL) is an aggressive subtype of non-Hodgkin lymphoma characterized by short survival wit

116 patients with relapsed or refractory kappa+ non-Hodgkin lymphoma/chronic lymphocytic leukemia (NHL/C

117 Non-Hodgkin lymphoma comprises a variety of neoplasms, m

118 pproval of rituximab for treatment of B cell non-Hodgkin lymphoma, development of monoclonal antibodi

119 homas worldwide and approximately 30% of the non-Hodgkin lymphomas diagnosed in the United States.

120 homa consists of mainly 4 subtypes of B-cell non-Hodgkin lymphoma: EMZL, FL, MCL, and DLBCL.

121 pproximately 40% of patients with Hodgkin or non-Hodgkin lymphoma express the type II latency Epstein

122 -associated T-cell lymphoma (EATL) is a rare non-Hodgkin lymphoma frequently associated with celiac d

123 mphomas (PTCLs) are a heterogeneous group of non-Hodgkin lymphomas frequently associated with poor pr

124 l, bladder, pancreatic, or gastric cancer or non-Hodgkin lymphoma from 2002 to 2011.

125 The resulting non-Hodgkin lymphoma gene sensor showed a detection limi

126 highly selective, label-free sensor for the non-Hodgkin lymphoma gene, with an aM detection limit, u

127 Treatment of non-Hodgkin lymphoma has changed profoundly, benefiting

128 The treatment of non-Hodgkin lymphomas has benefited enormously from the

129 Non-Hodgkin lymphomas have a wide range of histological

130 mpts to intensify chemotherapy in aggressive non-Hodgkin lymphomas have, however, proved ineffective

131 tic, prostate, liver/intrahepatic bile duct, non-Hodgkin lymphoma, head/neck, ovarian, or esophageal

132 In human non-Hodgkin lymphomas, high expression of Bcl-2 but not

133 cute lymphocytic leukemia, multiple myeloma, non-Hodgkin lymphoma, Hodgkin lymphoma, myeloproliferati

134 myeloma (HR, 1.28 [95% CI, 1.01-1.62]), and non-Hodgkin lymphoma (HR, 1.16 [95% CI, >1.00-1.35]) can

135 ssue disease was diagnosed in 30% and B-cell non-Hodgkin lymphoma in 22%, whereas the CryoVas was con

136 mphoma (MLBL) represents 2% of mature B-cell non-Hodgkin lymphoma in patients </= 18 years of age.

137 The prognosis of HIV-infected patients with non-Hodgkin lymphoma in the highly active antiretroviral

138 ar lymphoma (FL) is the most common indolent non-Hodgkin lymphoma in the Western hemisphere.

139 ymphoma (FL), the second most common type of non-Hodgkin lymphoma in the western world, is characteri

140 ular lymphoma (FL) is the second most common non-Hodgkin lymphoma in the Western world.

141 homa (FL) constitutes the second most common non-Hodgkin lymphoma in the western world.

142 phoma, is also expressed by several types of non-Hodgkin lymphoma, including a subset of diffuse larg

143 normal germinal center B cells as well as in non-Hodgkin lymphomas, including follicular lymphoma, di

144 lodysplastic syndrome (MDS), and Hodgkin and non-Hodgkin lymphomas increased by 45%, from 2,520 to 3,

145 sion phase (n = 179), patients with indolent non-Hodgkin lymphoma (iNHL), chronic lymphocytic leukemi

146 study in 64 patients with relapsed indolent non-Hodgkin lymphoma (iNHL).

147 a of the lung/bronchus (IRR, 1.58; P < .01), non-Hodgkin lymphoma (IRR, 1.41; P < .01), and breast ca

148 tion of follicular lymphoma to an aggressive non-Hodgkin lymphoma is a critical biologic event with p

149 Worldwide, B cell non-Hodgkin lymphoma is the most common hematological ma

150 ymphoma, the most common indolent subtype of non-Hodgkin lymphoma, is associated with a relatively lo

151 ell lymphoma (MCL), an aggressive subtype of non-Hodgkin lymphoma, is characterized by the hallmark t

152 ients with relapsed or refractory aggressive non-Hodgkin lymphoma, is efficacious and tolerable.

153 diffuse large B-cell lymphoma, a subtype of non-Hodgkin lymphoma, is rituximab, cyclophosphamide, do

154 cal HL was 5.3 (95% CI, 3.0 to 8.8), and for non-Hodgkin lymphoma, it was 1.9 (95% CI, 1.3 to 2.6).

155 atients with limited-stage aggressive B-cell non-Hodgkin lymphoma (LD-NHL).

156 Hematologic malignancies, including non-Hodgkin lymphoma, leukemia, Hodgkin lymphoma, and mu

157 sion lymphoma (PEL) is an aggressive type of non-Hodgkin lymphoma localized predominantly in body cav

158 -TBNA in subtyping lymphomas into high-grade non-Hodgkin lymphoma, low-grade non-Hodgkin lymphoma, an

159 cer-attributable deaths were associated with non-Hodgkin lymphoma, lung cancer, and liver cancer.

160 tourinary cancers other than bladder cancer, non-Hodgkin lymphoma, lung cancer, leukaemia other than

161 In 15 non-Hodgkin lymphomas, many more sst2 sites were labeled

162 Seven cancers (non-Hodgkin lymphoma, Merkel cell carcinoma, gastric ade

163 em; thyroid; mesothelioma; Hodgkin lymphoma; non-Hodgkin lymphoma; multiple myeloma; leukemia; and al

164 hronic lymphocytic leukemia (CLL; n = 41) or non-Hodgkin lymphoma (n = 145).

165 tAML risks increased after chemotherapy for non-Hodgkin lymphoma (n = 158; Poisson regression Ptrend

166 ing the study were attributed to progressive non-Hodgkin lymphoma (n = 2), treatment-related sepsis (

167 lastic lymphoma (n = 1, 6%), and unspecified non-Hodgkin lymphoma (n = 2, 11%).

168 , chronic lymphocytic leukemia (n = 24), and non-Hodgkin lymphoma (n = 62).

169 e myeloid leukemia (n=65), 39% in aggressive non-Hodgkin lymphoma (n=83), and 37% in indolent or mant

170 nts, black recipients had lower incidence of non-Hodgkin lymphoma (NHL) (adjusted incidence rate rati

171 m melanoma (RR = 8.75; 95% CI: 1.89, 40.53), non-Hodgkin lymphoma (NHL) (RR = 2.69; 95% CI: 1.33, 5.4

172 renewed interest as a therapeutic target in non-Hodgkin lymphoma (NHL) and chronic lymphocytic leuke

173 d young adults with Hodgkin lymphoma (HL) or non-Hodgkin lymphoma (NHL) and compared the biodistribut

174 ate adjusted incidence rate ratios (aIRR) of non-Hodgkin lymphoma (NHL) and other cancers with increa

175 eases, demonstrating therapeutic activity in non-Hodgkin lymphoma (NHL) and systemic lupus erythemato

176 Central nervous system (CNS) relapse in non-Hodgkin lymphoma (NHL) carries a very poor prognosis

177 National Comprehensive Cancer Network (NCCN) Non-Hodgkin Lymphoma (NHL) Database, a prospective cohor

178 's syndrome (pSS) confers increased risk for non-Hodgkin lymphoma (NHL) development.

179 dioimmunotherapy (PRIT) that targets CD20 in non-Hodgkin lymphoma (NHL) exhibits remarkable efficacy

180 mining prognosis in patients with aggressive non-Hodgkin lymphoma (NHL) for the past 20 years.

181 The association between benzene exposure and non-Hodgkin lymphoma (NHL) has been the subject of debat

182 Patients with relapsed or refractory (R/R) non-Hodgkin lymphoma (NHL) have a poor prognosis and lim

183 ious studies have reported that survivors of non-Hodgkin lymphoma (NHL) have an increased risk of dev

184 Patients with relapsed or refractory B-cell non-Hodgkin lymphoma (NHL) have an unfavourable prognosi

185 Treatment and prognosis of pediatric non-Hodgkin lymphoma (NHL) have improved dramatically in

186 s (1987-2014), we studied PCNSL and systemic non-Hodgkin lymphoma (NHL) in 288 029 solid organ transp

187 have been associated with increased risk of non-Hodgkin lymphoma (NHL) in HIV-infected populations.

188 The incidence of non-Hodgkin lymphoma (NHL) in human immunodeficiency vir

189 Little is known about the risk of non-Hodgkin lymphoma (NHL) in nonsmokers who are exposed

190 Non-Hodgkin lymphoma (NHL) is the most common AIDS-defin

191 Background: Non-Hodgkin lymphoma (NHL) is the most common AIDS-defin

192 Non-Hodgkin lymphoma (NHL) is the most commonly diagnose

193 Dietary fat intake may contribute to non-Hodgkin lymphoma (NHL) pathogenesis by influencing c

194 t to hypothetical myeloablative treatment of non-Hodgkin lymphoma (NHL) patients using (131)I-tositum

195 g of the burden of Kaposi's sarcoma (KS) and non-Hodgkin lymphoma (NHL) relative to antiretroviral th

196 lignancies significantly, many patients with non-Hodgkin lymphoma (NHL) remain incurable.

197 ommon immune system-altering experiences and non-Hodgkin lymphoma (NHL) risk using a case-control stu

198 The distribution of non-Hodgkin lymphoma (NHL) subtypes differs around the w

199 Several non-Hodgkin lymphoma (NHL) subtypes, including diffuse l

200 a-2 (BCL-2) overexpression is common in many non-Hodgkin lymphoma (NHL) subtypes.

201 homa (PTCL) is a rare, heterogeneous type of non-Hodgkin lymphoma (NHL) that, in general, is associat

202 This analysis examined the association of non-Hodgkin lymphoma (NHL) with prediagnostic carotenoid

203 carcinoma, gastric cancer, Burkitt lymphoma, non-Hodgkin lymphoma (NHL), and Hodgkin lymphoma.

204 n genetic variants have been associated with non-Hodgkin lymphoma (NHL), but individual study results

205 ediates superior disease control of systemic non-Hodgkin lymphoma (NHL), it fails to completely elimi

206 between polychlorinated biphenyls (PCBs) and non-Hodgkin lymphoma (NHL), occupational cohort studies

207 s and the improved survival of patients with non-Hodgkin lymphoma (NHL), relapses or primary refracto

208 In murine xenograft models of MM and non-Hodgkin lymphoma (NHL), the CD38-bispecific construc

209 regulation is an established risk factor for non-Hodgkin lymphoma (NHL), the importance of subclinica

210 In Non-Hodgkin Lymphoma (NHL), the prevalence of OBI reacti

211 apsed chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL), they require prolonged admin

212 eveloped Hodgkin lymphoma (HL), 38 developed non-Hodgkin lymphoma (NHL), three developed T-cell proly

213 optive immunotherapy treatment for B-lineage non-Hodgkin lymphoma (NHL), we expanded T cells from cli

214 d blinatumomab in relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

215 netic variations are associated with risk of non-Hodgkin lymphoma (NHL).

216 ral suspected environmental risk factors for non-Hodgkin lymphoma (NHL).

217 are well established for adult patients with non-Hodgkin lymphoma (NHL).

218 tivity of this agent in patients with B-cell non-Hodgkin lymphoma (NHL).

219 in patients with relapsed/refractory B-cell non-Hodgkin lymphoma (NHL).

220 t of patients with Hodgkin lymphoma (HL) and non-Hodgkin lymphoma (NHL).

221 etween infection with GB virus-C (GBV-C) and non-Hodgkin lymphoma (NHL).

222 antation (HCT) can potentially cure indolent non-Hodgkin lymphoma (NHL).

223 ression was used to confirm the diagnosis of non-Hodgkin lymphoma (NHL).

224 f relapsed/refractory CD20(+)/CD22(+) B-cell non-Hodgkin lymphoma (NHL).

225 174 patients with newly diagnosed aggressive non-Hodgkin lymphoma (NHL).

226 is associated with a high risk of developing non-Hodgkin lymphoma (NHL).

227 represent attractive targets for therapy in non-Hodgkin lymphoma (NHL).

228 d with heart failure (HF) among survivors of non-Hodgkin lymphoma (NHL).

229 ytes is associated with an increased risk of non-Hodgkin lymphoma (NHL).

230 of a potential novel risk factor for B-cell non-Hodgkin lymphoma (NHL).

231 erapy for relapsed intermediate-grade B-cell non-Hodgkin lymphoma (NHL); however, relapse rates are h

232 signature defining aggressiveness in B-cell non-Hodgkin lymphomas (NHL) and assessed whether this si

233 defining cancers (ADCs; Kaposi sarcoma [KS], non-Hodgkin lymphoma [NHL], and cervical cancer) among h

234 osition to lymphoma (collectively defined as non-Hodgkin lymphoma [NHL], Hodgkin lymphoma [HL], and c

235 nt activity of 22% to 68% in relapsed B-cell non-Hodgkin lymphoma(NHL).

236 Non-Hodgkin lymphomas (NHLs) are the most common cancer

237 ogic and anatomic subtypes of carcinomas and non-Hodgkin lymphomas (NHLs) of the stomach and esophagu

238 se (LDR) of 46 patients with indolent B-cell non-Hodgkin lymphomas (NHLs) or chronic lymphocytic leuk

239 Over 22 y, we identified 1324 non-Hodgkin lymphomas (NHLs), 285 multiple myelomas, and

240 often constitutively activated in GC-derived non-Hodgkin lymphomas (NHLs).

241 Cutaneous T cell lymphoma (CTCL) is a non-Hodgkin lymphoma of skin-homing T lymphocytes.

242 neous T-cell lymphoma (CTCL) is an incurable non-Hodgkin lymphoma of the skin-homing T cell.

243 mposite lymphomas can be combinations of two non-Hodgkin lymphomas or a combination of a non-Hodgkin

244 mary tumor cells isolated from patients with non-Hodgkin lymphomas or chronic lymphocytic leukemia an

245 emotherapy and a diagnosis of breast cancer, non-Hodgkin lymphoma, or gynecologic cancers.

246 with cancer of the lung, prostate, thyroid, non-Hodgkin lymphoma, or hematological cancer in either

247 for acute lymphoid leukaemia (p<0.0001) and non-Hodgkin lymphoma (p<0.0001 in AYAs and p=0.023 in ch

248 e breast, lung/bronchus, endometrial, colon, non-Hodgkin lymphoma, pancreas, kidney/renal pelvis, rec

249 Previously, we observed FOXO1 mutations in non-Hodgkin lymphoma patient samples.

250 nondosimetric factors predicting outcome of non-Hodgkin lymphoma patients after (131)I-tositumomab r

251 for 130 tumors in 39 relapsed or refractory non-Hodgkin lymphoma patients by coupling SPECT/CT imagi

252 e list of bacteria that promote human B-cell non-Hodgkin lymphoma, possibly by the infection of pDCs

253 ell lymphoma (MCL) is an uncommon subtype of non-Hodgkin lymphoma previously considered to have a poo

254 in relapsed or refractory peripheral T-cell non-Hodgkin lymphoma (PTCL).

255 A middle-aged man with non-Hodgkin lymphoma received chemotherapy and a stem ce

256 logically documented, CD20-positive indolent non-Hodgkin lymphoma refractory to rituximab were enroll

257 ll lymphoma (DLBCL), the most common type of non-Hodgkin lymphoma, remains a partially curable diseas

258 Non-Hodgkin lymphoma represents a wide spectrum of illne

259 an international, multicohort retrospective non-Hodgkin lymphoma research study, retrospectively eva

260 argets overexpressed in multiple myeloma and non-Hodgkin lymphoma, respectively.

261 n the RICOVER study of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL) were investiga

262 rolled in studies from the German High-Grade Non-Hodgkin Lymphoma Study Group and the MabThera Intern

263 we analyzed 11 consecutive German High-Grade Non-Hodgkin Lymphoma Study Group trials.

264 e-adjusted IPI 2,3) of the German High-Grade Non-Hodgkin Lymphoma Study Group were analyzed with the

265 prospective trials of the German High-Grade Non-Hodgkin lymphoma Study Group.

266 Analysis of an NHL (non-Hodgkin lymphoma) study with SNP measurements shows

267 randomisation scheme stratified by indolent non-Hodgkin lymphoma subtype, rituximab-refractory type,

268 esholds may require inclusion of homogeneous non-Hodgkin lymphoma subtypes to account for differences

269 hemodynamics, we characterized two exemplary non-Hodgkin lymphoma subtypes with comparable CD20 expre

270 s also demonstrated efficacy in other B-cell non-Hodgkin lymphoma subtypes, in particular mantle cell

271 egistries and allowed reporting on the major non-Hodgkin lymphoma subtypes.

272 g myelodysplastic syndromes, acute leukemia, non-Hodgkin lymphomas such as chronic lymphocytic leukem

273 urkitt lymphoma (BL) is an aggressive B-cell non-Hodgkin lymphoma that is almost uniformly associated

274 mphoma (NKTCL) is a rare, aggressive form of non-Hodgkin lymphoma that is generally incurable at more

275 ymphoma (PCNSL) is a rare form of extranodal non-Hodgkin lymphoma that is typically confined to the b

276 ll lymphoma (ALCL) is a CD30-positive T-cell non-Hodgkin lymphoma that morphologically resembles ALK-

277 pensity to transform to an aggressive B-cell non-Hodgkin lymphoma that underscores the importance of

278 eloid leukemia, myelodysplastic syndrome, or non-Hodgkin lymphoma, the three most common indications

279 n for the down-regulation of PML observed in non-Hodgkin lymphomas, thereby suggesting a novel therap

280 e overall survival of patients with indolent non-Hodgkin lymphomas, these lymphomas remain largely in

281 ular lymphoma (FL) tumors, contrasting other non-Hodgkin lymphoma TILs.

282 been conducted on 3 clinical cases: case 1, non-Hodgkin lymphoma treated with (131)I-tositumomab; ca

283 The OR for non-Hodgkin lymphoma was increased at 1.22 (95% confiden

284 A positive association for B-cell non-Hodgkin lymphoma was noted only in those with a diag

285 o rituximab in patients with indolent B-cell non-Hodgkin lymphoma was tolerable but did not lead to i

286 patients with relapsed CD37+ indolent B-cell non-Hodgkin lymphoma were included for RM dosimetry.

287 patients with relapsed/refractory aggressive non-Hodgkin lymphoma were randomized to GDP or DHAP; 87

288 accounts for about 10% of all lymphomas) and non-Hodgkin lymphoma, which is the topic of this Seminar

289 Patients with indolent non-Hodgkin lymphoma who fail to achieve adequate diseas

290 nts with histologically confirmed aggressive non-Hodgkin lymphoma who had relapsed after two or more

291 rvous system (CNS) lymphoma is an aggressive non-Hodgkin lymphoma with poor prognosis.

292 ients (age >/=18 years) with indolent B-cell non-Hodgkin lymphoma with stable disease or better lasti

293 DLBCL) is the most common aggressive form of non-Hodgkin lymphoma with variable biology and clinical

294 mphomas (PTCLs) represent a diverse group of non-Hodgkin lymphomas with a poor prognosis and no accep

295 PTCL) is a heterogeneous group of aggressive non-Hodgkin lymphomas with poor outcomes on current ther

296 rituximab-refractory patients with indolent non-Hodgkin lymphoma, with manageable toxicity, and is a

297 ymphoma (FL) represents more than 20% of all non-Hodgkin lymphomas worldwide and approximately 30% of

298 cytotoxic retinoid, upon growth kinetics in non-Hodgkin lymphoma xenografts.

299 mphoma (DLBCL) is the most common subtype of non-Hodgkin lymphoma, yet 40% to 50% of patients will ev

300 oma (FL) is the most common form of indolent non-Hodgkin lymphoma, yet it remains only partially char